1
Albert Duranton: Modulating body/cranial hair growth with lipoxygenase/cyclooxygenase inhibitors. Societe L Oreal, Burns Doane Swecker & Mathis L, July 27, 1999: US05928654 (17 worldwide citation)

The loss of body/cranial hair is promoted and/or its growth is slowed/prevented by topically and/or systemically administering to an individual in need of such treatment respectively effective amounts at least one lipoxygenase inhibitor and at least one cyclooxygenase inhibitor, or alternatively, an ...


2
Albert Duranton, Olivier De Lacharriere: Modulating body/cranial hair growth. Societe l&apos Oreal, Burns Doane Swecker & Mathis L, October 15, 2002: US06465421 (13 worldwide citation)

The growth of body and/or head/cranial hair on mammalian organisms, for example humans, is modulated by administering thereto, whether topically and/or systemically, therapeutically effective amounts of at least one lipoxygenase or cyclooxygenase inhibitor, or at least one lipoxygenase or cyclooxyge ...


3
Albert Duranton: Cosmetic kit including an indicator or sensor of ambient humidity. L Oreal, Oliff & Berridge, March 31, 2009: US07509839 (10 worldwide citation)

A kit includes at least one of: a substance for one of ingestion by a human body and application to one of the skin, the mucous membranes, hair, and the nails; a cosmetic applicator; and a makeup accessory. The kit also includes at least one of: an indicator of ambient humidity; and a sensor of ambi ...


4
Francis Pruche, Albert Duranton, Nathalie Boyera, Brigitte Gautier: Method to promote, stimulate and/or delay hair loss by a brady kinin antagonist. Societe L&apos Oreal, Burns Doane Swecker & Mathis L, October 22, 2002: US06468972 (10 worldwide citation)

The present invention is directed to a method to promote, stimulate and/or delay hair loss by administering an effective amount of at least one bradykinin antagonists to promote, stimulate and/or delay hair loss to an individual in need thereof.


5
Yann F Mahe, Albert Duranton: Use of a peptide preventing the intolerance reactions of the skin, in particular in cosmetic compositions. L&apos Oreal, Oliff & Berridge, March 19, 2002: US06358929 (3 worldwide citation)

Use as additives, in cosmetic compositions, of a peptide containing the sequence Lysine-Proline-Valine, with the aim of preventing or reducing the intolerance reactions linked to a contact hypersensitivity.


6

7
Albert Duranton, Isabelle Hansenne: Use of alkyl polyglycosides and/or of O-acylated derivatives of glucose for treating hair loss. L&apos Oreal, Jacobson Price Holman & Stern PLLC, March 20, 2001: US06203783 (1 worldwide citation)

Cosmetic or pharmaceutical use of alkylpolyglycosides and/or O-acylated derivatives of glucose for treating hair loss. The compounds have the developed formula (II) where R


8
Albert Duranton, Lionel Breton: Use of taurine for treating alopecia. L OREAL, NESTEC, Oliff, September 22, 2015: US09138408

The invention relates to a method of treating and preventing ageing of the pilosebaceous unit and/or alopecia in human through the administration of taurine and/or hypotaurine and/or the acceptable salts thereof in an oral composition. Specifically, the invention relates to a method of treating and ...


9
Albert Duranton, Isabelle Hansenne: Use in cosmetics or pharmacy of alkyl polyglycosides and/or o-acyl derivatives of glucose for the treatment of hair loss. Oreal, February 12, 1993: FR2680103-A1

Cosmetic or pharmaceutical use of alkylpolyglycosides and/or O-acylated derivatives of glucose for treating hair loss. The compounds have the developed formula (II) where R1 is a radical or a mixture of alkyl or alkenyl radicals; x is from 1 to 15; and/or compounds of the formula (III) where R2 stan ...


10
Albert Duranton, Christine Collin Djangone, Francis Pruche, Jean Thierry Simonnet: Topical administration of at least one double-stranded RNA oligonucleotide (dsRNA). L Oreal, Buchanan Ingersoll & Rooney PC, April 21, 2015: US09012418

Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to said differentiated cells a thus effective amount of at least one double-stranded RNA oligonucleotide, for ...